K 001

Drug Profile

K 001

Alternative Names: K-001; Peptidoglycan complex of spirulina

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hwealth Pharmaceutical; Shanghai Jiaotong University School of Medicine
  • Developer Shanghai Jiaotong University School of Medicine
  • Class Amino acids; Antineoplastics; Polysaccharides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pancreatic cancer

Most Recent Events

  • 22 Nov 2017 K 001 has patent protection in China, Japan and USA
  • 17 Nov 2017 Hwealth Pharmaceutical and Shanghai Jiaotong University School of Medicine plans a phase II/III trial for Pancreatic cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in China (ChiCTR-IIR-17013424)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top